Bioxytran, Inc. (BIXT) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Bioxytran, Inc. (BIXT) trades at $0.0238 with AI Score 46/100 (Grade C). Bioxytran, Inc. is a biotechnology firm focused on developing innovative treatments for oxygen deficiency. Market cap: $2.72M, Sector: Healthcare.
Price as of Jul 23, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for BIXT: BIXT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BIXT against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BIXT: 1/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Bioxytran, Inc. (BIXT) Healthcare & Pipeline Overview
Bioxytran, Inc. specializes in developing therapeutic solutions for hypoxia-related conditions, leveraging proprietary technologies to enhance oxygen delivery and improve patient outcomes in critical health scenarios.
What Is the Investment Thesis for BIXT?
Bioxytran, Inc. presents an intriguing investment thesis centered on its innovative product pipeline and the growing demand for treatments addressing hypoxia. The primary growth catalyst is the advancement of BXT-25 through clinical trials, with potential market entry projected within the next few years, targeting a significant addressable market in stroke recovery and wound care. Additionally, ProLectin-Rx offers a unique approach to treating Covid-19, capitalizing on the ongoing need for effective therapies in the post-pandemic landscape. However, the company faces risks associated with its OTC market listing, including liquidity and volatility concerns, which may impact investor sentiment. Monitoring clinical trial outcomes and securing additional funding will be critical for Bioxytran's future growth and operational sustainability.
Based on FMP financials and quantitative analysis
BIXT Key Highlights
- Market Cap: $0.00B, indicating a nascent stage in market presence.
- Beta: 1.82, suggesting higher volatility compared to the market.
- Employees: 3, reflecting a focused operational structure.
- Dividend Yield: None, as the company reinvests in R&D.
- Clinical Development Phase: Key focus on innovative therapies for hypoxia.
Who Are BIXT's Competitors?
BIXT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMGN Amgen Inc. | $369.39 | +0.91% | $200B | 83 |
| GILD Gilead Sciences, Inc. | $129.80 | -0.41% | $161B | 94 |
| REGN Regeneron Pharmaceuticals, Inc. | $649.90 | -0.20% | $67.0B | 91 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.35% | $7.58M | 72 |
| BLRX BioLineRx Ltd. | $2.86 | +0.41% | $12.4M | 69 |
| GBIO Generation Bio Co. | $5.34 | +0.00% | $36.0M | 69 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.16 | +3.48% | $170M | 75 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BIXT's Key Strengths?
- Innovative product pipeline targeting critical health issues.
- Focused approach on hypoxia-related therapies.
- Small team allows for agile and efficient operations.
What Are BIXT's Weaknesses?
- Limited financial resources and market presence.
- High dependency on successful clinical trial outcomes.
- Small employee base may limit operational capacity.
What Could Drive BIXT Stock Higher?
- Clinical trial results for BXT-25 expected in Q3 2026.
- Development of ProLectin-Rx for Covid-19 treatment.
- Potential partnerships for funding and resource sharing.
What Are the Key Risks for BIXT?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles in obtaining drug approvals.
- Market volatility impacting stock price and investor sentiment.
- Dependence on successful outcomes from clinical trials.
What Are the Growth Opportunities for BIXT?
- Growth opportunity 1: The development of BXT-25 presents a significant growth opportunity, targeting the stroke recovery market, which is projected to reach $34 billion by 2026. With an aging population and increasing stroke incidence, Bioxytran's innovative approach to oxygen delivery could capture a substantial share of this market, especially if clinical trials demonstrate efficacy and safety.
- Growth opportunity 2: ProLectin-Rx aims to address mild to moderate cases of Covid-19, a market that remains relevant as new variants emerge. The global market for Covid-19 treatments is expected to exceed $50 billion, providing Bioxytran with an opportunity to establish itself as a key player in this space by leveraging its unique mechanism of action against galectin-1.
- Growth opportunity 3: As the understanding of hypoxia-related conditions expands, Bioxytran could explore additional indications for BXT-25 beyond strokes and wound care, potentially entering markets for other hypoxia-related diseases. This could significantly broaden the company's addressable market and enhance its revenue potential.
- Growth opportunity 4: Collaborations with larger pharmaceutical companies for co-development or licensing agreements could provide Bioxytran with the necessary resources and expertise to accelerate its product development timeline. Such partnerships could also enhance credibility and market access for its therapies.
- Growth opportunity 5: The increasing focus on rare diseases and orphan drugs presents an opportunity for Bioxytran to position its products as specialized therapies, possibly qualifying for incentives such as orphan drug designation, which could facilitate faster regulatory approval and market exclusivity.
What Opportunities Does BIXT Have?
- Growing demand for treatments addressing hypoxia.
- Potential for partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic indications for existing products.
What Threats Does BIXT Face?
- Regulatory hurdles in drug approval processes.
- Intense competition from established biotechnology firms.
- Market volatility and liquidity risks associated with OTC listings.
What Are BIXT's Competitive Advantages?
- Proprietary technology for oxygen delivery through BXT-25.
- Focused expertise in hypoxia-related therapies.
- Potential for unique market positioning in a niche area.
- Small operational team allows for agile decision-making and innovation.
- Strong intellectual property strategy to protect product development.
What Does BIXT Do?
Founded in 2008 and headquartered in Newton, Massachusetts, Bioxytran, Inc. is a pharmaceutical company dedicated to developing treatments for oxygen deficiency, also known as hypoxia. The company is currently in the clinical development phase, focusing on innovative therapies that address critical health challenges. Its lead product, BXT-25, is a small oxygen-transporting molecule derived from bovine hemoglobin, stabilized by a co-polymer. This drug is designed to combat oxygen deprivation in the brain resulting from strokes and to treat wound hypoxia, which can lead to tissue death if left unaddressed. Additionally, Bioxytran is advancing ProLectin-Rx, a pectin-based polysaccharide aimed at inhibiting galectin-1 to provide therapeutic benefits for mild to moderate cases of Covid-19. The company operates with a small team of three employees, reflecting its focused approach to research and development. As it continues to navigate the complexities of the biotechnology landscape, Bioxytran aims to position itself as a key player in addressing unmet medical needs related to oxygen delivery and hypoxia management.
What Products and Services Does BIXT Offer?
- Develops innovative therapies for oxygen deficiency (hypoxia).
- Focuses on clinical development of medicinal treatments.
- Key product BXT-25 targets oxygen deprivation in stroke patients.
- Advances ProLectin-Rx for treating mild to moderate Covid-19.
- Utilizes proprietary technologies based on bovine hemoglobin.
- Operates primarily in the United States with potential global applications.
How Does BIXT Make Money?
- Primarily generates revenue through the development and commercialization of pharmaceutical products.
- Focuses on clinical trials to validate product efficacy and safety.
- Seeks partnerships and collaborations for funding and resource sharing.
- Plans to monetize products through direct sales and licensing agreements.
- Invests in research and development to enhance product pipeline.
What Industry Does BIXT Operate In?
The biotechnology industry is characterized by rapid advancements in drug development and a growing focus on personalized medicine. With an increasing prevalence of conditions related to hypoxia, such as strokes and chronic wounds, the demand for effective therapeutic solutions is rising. Bioxytran, Inc. operates within this dynamic landscape, positioning itself to capitalize on the need for innovative treatments. The global biotechnology market is expected to grow significantly, driven by technological advancements and an increasing number of clinical trials. As a small player in this space, Bioxytran faces competition from larger, established firms but benefits from its specialized focus on hypoxia-related therapies.
Who Are BIXT's Key Customers?
- Healthcare providers and hospitals treating stroke patients.
- Pharmaceutical companies interested in licensing innovative therapies.
- Patients suffering from hypoxia-related conditions.
- Government and non-profit organizations focused on public health.
- Investors seeking opportunities in biotechnology and healthcare sectors.
F-Score 2/9Financial Health
Bioxytran, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
BIXT Valuation & Market Position
With a $2.72M market cap, Bioxytran, Inc. sits in the micro-cap segment of the market. Relative to its peer group, BIXT's quantitative score of 46/100 is below the peer average of 82/100.
ROE 91%Key Financial Metrics
Return on equity for Bioxytran, Inc. stands at 90.6%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -21.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.09 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -97.2%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Bioxytran, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Newton, US. The company is led by CEO David Platt. BIXT has traded publicly since 2010.
BIXT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Innovative product pipeline targeting critical health issues.
- Focused approach on hypoxia-related therapies.
- Small team allows for agile and efficient operations.
- Upcoming: Clinical trial results for BXT-25 expected in Q3 2026.
Bear Case
- Limited financial resources and market presence.
- High dependency on successful clinical trial outcomes.
- Small employee base may limit operational capacity.
- Potential: Regulatory hurdles in obtaining drug approvals.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
BIXT Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
BIXT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BIXT.
Price Targets
Wall Street price target analysis for BIXT.
BIXT MoonshotScore
What does this score mean?
The MoonshotScore rates BIXT 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: David Platt
CEO
David Platt has extensive experience in the biotechnology sector, having held various leadership roles in pharmaceutical companies prior to founding Bioxytran, Inc. He holds a degree in biochemistry and has a strong background in drug development and regulatory affairs. His expertise encompasses both the scientific and business aspects of biotechnology, making him well-suited to lead Bioxytran's innovative initiatives.
Track Record: Under David Platt's leadership, Bioxytran has successfully advanced its product pipeline, particularly BXT-25, through early-stage development. His strategic vision has positioned the company to explore critical partnerships and funding opportunities to support ongoing research.
BIXT OTC Market Information
The OTC Other tier includes companies that do not meet the higher listing standards of the NYSE or NASDAQ but still provide investment opportunities. This tier often features smaller companies with less liquidity and visibility, which can lead to higher volatility in stock prices.
- OTC Tier: OTC Other
- Limited financial resources may hinder operational growth.
- High volatility and liquidity risks associated with OTC market.
- Regulatory uncertainties in the biotechnology industry.
- Verify the company's clinical trial progress and results.
- Assess the financial health and funding sources.
- Review the competitive landscape and market positioning.
- Examine the management team's experience and track record.
- Investigate potential partnerships or collaborations.
- Presence of a qualified management team with industry experience.
- Engagement in clinical trials and research initiatives.
- Adherence to regulatory compliance standards.
What Investors Ask About Bioxytran, Inc. (BIXT) — Healthcare
What does the AI Score mean for BIXT?
BIXT holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Bioxytran, Inc. is a biotechnology firm focused on developing innovative treatments for oxygen deficiency. Its key products include BXT-25 for stroke-related hypoxia and ProLectin-Rx for Covid-19 …
What does Bioxytran, Inc. do?
Bioxytran, Inc. is a biotechnology company focused on developing innovative therapies to address oxygen deficiency (hypoxia). Its primary product, BXT-25, is designed to enhance oxygen delivery in patients suffering from conditions such as strokes. Additionally, the company is advancing ProLectin-Rx, a treatment targeting mild to moderate Covid-19 cases.
What are the main risks for BIXT?
Bioxytran, Inc. faces several risks, including regulatory hurdles in obtaining necessary approvals for its drug candidates, which could delay market entry. Additionally, the company operates in the OTC market, exposing it to higher volatility and liquidity risks. The success of its clinical trials is critical, as unfavorable results could significantly impact its future prospects.
How does Bioxytran, Inc. navigate regulatory approval processes?
Bioxytran, Inc. is committed to adhering to regulatory standards set by agencies such as the FDA. The company focuses on conducting rigorous clinical trials to demonstrate the safety and efficacy of its products, which is essential for gaining approval. By maintaining compliance and engaging with regulatory bodies, Bioxytran aims to streamline its approval processes and minimize delays.
What are the key factors to evaluate for BIXT?
Bioxytran, Inc. (BIXT) holds an AI score of 46/100 (low). Not financial advice.
How frequently does BIXT data refresh on this page?
BIXT's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BIXT's recent stock price performance?
Bioxytran, Inc. (BIXT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product pipeline targeting critical health issues. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BIXT overvalued or undervalued right now?
Bioxytran, Inc. (BIXT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research BIXT before investing?
Before investing in Bioxytran, Inc. (BIXT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided is based on available data and may be subject to change as the company evolves.